 LEXINGTON, Mass., Dec. 9, 2020 PRNewswire -- Curis, Inc. NASDAQ:CRIS, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a... 